Name: Biosimilar for Patients on Denosumab
Start: 2024-10-24T13:00:00-04:00
End: 2024-10-24T14:00:00-04:00

Man and woman sitting on couch reading tablet

WEBINAR

Biosimilar for Patients on Denosumab

Jubbonti® is the first and only Health Canada-approved denosumab biosimilar for osteoporosis and increasing bone mass. What does this mean for patients?

Join Dr. Teri Charrois who will discuss what a biologic and biosimilar are, how Jubbonti® differs from the Prolia® brand, what you need to know when speaking with your healthcare provider and more.

Register

Webinar Details

Date: Thursday, October 24, 2024

Time:

10:00 am – 11:00 am PT
11:00 am – 12:00 pm MT
12:00 pm – 1:00 pm CT
1:00 pm – 2:00 pm ET
2:00 pm – 3:00 pm AT
2:30 pm – 3:30 pm NT

Register

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

Address(Required)

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

How did you hear about the webinar?

If you would like to submit a question in advance, please submit below. We will do our best to address all questions during the webinar.

PRESENTER

Teri Charrois BSc Pharm, MSc

Dr. Teri Charrois is currently the Associate Dean of Practice Innovation and Professor of Teaching at UBC Faculty of Pharmaceutical Sciences. Dr. Charrois graduated with her BScPharm from the University of Alberta (UofA) and then went on to complete an accredited pharmacy residency program followed by working as an internal medicine pharmacist before finishing her master’s degree in clinical epidemiology. In 2014, she joined the UofA Faculty of Pharmacy and Pharmaceutical Sciences as Academic Lead of Practice Innovation. During that time, she completed her Doctor of Education with a focus on adult learning and decision-making.

Dr. Charrois was the first pharmacist in the Northern Alberta Osteoporosis Program and provides clinical care in the Multidisciplinary Bone Health Clinic with the Division of Rheumatology at the University of Alberta.